FDA Expands Joenja to Younger Children
FDA approved Joenja, leniolisib, for children aged four through eleven years with activated phosphoinositide 3-kinase delta syndrome who weigh at least 27 kilograms. The 40-milligram and 50-milligram twice-daily doses make Joenja the first FDA-approved…
